| Literature DB >> 35949650 |
Martin van Zyl1, Mariam Khabsa1, Jason A Tri1, Thomas P Ladas1, Omar Z Yasin1, Adetola O Ladejobi1, John Reilly2, Barry O'Brien2, Kenneth Coffey2, Samuel J Asirvatham1,3.
Abstract
This study aimed to evaluate the safety and acute effect on markers of cardiac autonomic tone following pulsed electric fields (PEFs) delivered to epicardial ganglionated plexi (GP) during a cardiac surgical procedure. Ablation of GP as a treatment for atrial fibrillation (AF) has shown promise, but thermal ablation energy sources are limited by the risk of inadvertent collateral tissue injury. In acute canine experiments, median sternotomy was performed to facilitate the identification of 5 epicardial GP regions using an anatomy-guided approach. Each site was targeted with saline-irrigated PEF (1000 V, 100 μs, 10 electrocardiogram [ECG]-synchronized pulse sequences). Atrial effective refractory period (AERP) and local electrogram (EGM) amplitude were measured before and after each treatment. Histology was performed on samples from treatment-adjacent structures. In 5 animals, 30 (n = 2) and 60 (n = 3) pulses were successfully delivered to each of the 5 target sites. There was no difference in local atrial EGM amplitude before and after PEF application at each site (1.83 ± 0.41 vs. 1.92 ± 0.53 mV, P = .72). The mean AERP increased from 97 ± 15 ms at baseline to 115 ± 7 ms following treatment at all sites (18.6% increase; 95% confidence interval, 1.9-35.2; P = .037). There were no sustained ventricular arrhythmias or acute evidence of ischemia following delivery. Histology showed complete preservation of adjacent atrial myocardium, phrenic nerves, pericardium, and esophagus. Use of PEF to target regions rich in cardiac GP in open-chest canine experiments was feasible and effective at acutely altering markers of cardiac autonomic tone. Copyright:Entities:
Keywords: Ganglionated plexi; atrial fibrillation; cardiac denervation; electroporation; pulsed electric fields
Year: 2022 PMID: 35949650 PMCID: PMC9359425 DOI: 10.19102/icrm.2022.130704
Source DB: PubMed Journal: J Innov Card Rhythm Manag ISSN: 2156-3977
Detailed Baseline and Post-treatment Data
| Animal # | Site | Target Energy Dose | No. of Pulses Delivered | Peak Heart Rate (bpm) | Blood Pressure S/D/M (mmHg) | AERP HRA (ms) | AERP CS (ms) | AERP LAA (ms) |
|---|---|---|---|---|---|---|---|---|
|
| Baseline | N/A | N/A | 113 | 79/51/60 | 80 | 120 | 130 |
| OSGP | 1000 V 100 μs | 10 × 3 | 121 | 152/110/124 | 60 | 120 | 130 | |
| RSGP | 1000 V 100 μs | 10 × 3 | 142 | 182/141/155 | 50 | 120 | 170 | |
| TSGP | 1000 V 100 μs | 10 × 3 | 111 | 163/112/129 | 50 | 120 | 170 | |
| LSGP | 1000 V 100 μs | 10 × 3 | 127 | 174/137/149 | 60 | 120 | 170 | |
| LMGP | 1000 V 100 μs | 10 × 3 | 121 | 127/93/104 | 70 | 120 | 190 | |
|
| Baseline | N/A | N/A | 104 | 75/45/55 | 60 | 100* | 60 |
| OSGP | 1000 V 100 μs | 10 × 3 | 108 | 102/68/79 | 60 | 130 | 90* | |
| RSGP | 1000 V 100 μs | 10 × 3 | 162 | 111/74/86 | 90* | 130 | 120* | |
| TSGP | 1000 V 100 μs | 10 × 3 | 164 | 110/77/88 | 50 | 90 | 110 | |
| LSGP | 1000 V 100 μs | 10 × 3 | 141 | 82/58/66 | 60 | 110 | 100 | |
| LMGP | 1000 V 100 μs | 10 × 3 | 138 | 125/86/99 | 80 | 130 | 120 | |
|
| Baseline | N/A | N/A | 117 | 81/67/72 | 70 | 80 | 130 |
| OSGP | 1000 V 100 μs | 10 × 6 | 111 | 240/172/195 | 100 | 80 | 140 | |
| RSGP | 1000 V 100 μs | 10 × 6 | 128 | 238/168/191 | 110 | 110 | 130 | |
| TSGP | 1000 V 100 μs | 10 × 6 | 123 | 195/148/164 | 130 | 120 | 130 | |
| LSGP | 1000 V 100 μs | 10 × 6 | 133 | 182/142/155 | 100 | 100 | 160 | |
| LMGP | 1000 V 100 μs | 10 × 6 | 122 | 162/126/138 | 110 | 90 | 140 | |
|
| Baseline | N/A | N/A | 94 | 106/63/77 | 90 | 120 | 90 |
| OSGP | 1000 V 100 μs | 10 × 6 | 107 | 156/120/132 | 120 | 150 | 110 | |
| RSGP | 1000 V 100 μs | 10 × 6 | 116 | 145/111/122 | 130 | 130 | 90 | |
| TSGP | 1000 V 100 μs | 10 × 6 | 114 | 139/113/122 | 120 | 110 | 100 | |
| LSGP | 1000 V 100 μs | 10 × 6 | 98 | 129/120/123 | 120 | 120 | 150 | |
| LMGP | 1000 V 100 μs | 10 × 6 | 84 | 124/98/106 | 100 | 130 | 120 | |
|
| Baseline | N/A | N/A | 152 | 80/55/63 | 120 | 100 | 110 |
| OSGP | 1000 V 100 μs | 10 × 6 | 137 | 81/56/64 | 140 | 130 | 150 | |
| RSGP | 1000 V 100 μs | 10 × 6 | 128 | 95/54/68 | 170 | 100 | 120 | |
| TSGP | 1000 V 100 μs | 10 × 6 | 142 | 110/72/85 | 150 | 100 | 130 | |
| LSGP | 1000 V 100 μs | 10 × 6 | 144 | 101/62/75 | 130 | 100 | 140 | |
| LMGP | 1000 V 100 μs | 10 × 6 | 149 | 96/65/75 | 110 | 110 | 110 |
Abbreviations: AERP, atrial effective refractory period; CS, coronary sinus; HRA, high right atrium; LAA, left atrial appendage; LMGP, ligament of Marshall ganglionated plexi; LSGP, left superior ganglionated plexi; OSGP, oblique sinus ganglionated plexi; RSGP, right superior ganglionated plexi; S/D/M, systolic/diastolic/mean; TSGP, transverse sinus ganglionated plexi. Vital signs and atrial effective refractory period response are stratified by each experimental animal and each energy delivery site. *Denotes values that were likely higher than the actual AERP due to pacing-induced arrhythmia interfering with interpretation.